Just speculating because Kevetrin hasn't targeted breast cancer in the past, but has already pursued ovarian cancer, that Kevetrin may be very effective against the BRCA gene mutation that affects about 20% of both cancers. If this in fact is Dr. Mennon's target, we are looking at a huge market and the upcoming ovarian cancer study may reveal effectiveness against this mutation thereby almost being a 2 for 1 study... at least in my mind. Of course a breast CA study will still have to be conducted but If I were looking to invest in a cancer drug, this would be exactly what I would be looking for.